Home > Inhibitors & Agonists > Metabolic Enzyme/Protease > Phospholipase
Cat. No. Product name CAS No.
DC11847 AZD2716

AZD2716(AZD-2716) is a novel potent, selective, orally bioavailable sPLA2 inhibitor with excellent plasma sPLA2 inhibition (IC50=0.1 nM).

1845753-81-2
DC9589 D609

D609 is a selective competitive phosphatidyl choline-specific phospholipase C (PC-PLC) inhibitor (Ki = 6.4 μM); antiviral and antitumor agent.

83373-60-8
DC7397 Darapladib

Darapladib is a selective and orally active inhibitor of Lp-PLA2 (IC50= 270 pM)

356057-34-6
DC7526 Varespladib Featured

LY315920 (Varespladib) is a potent and selective human non-pancreatic secretory phospholipase A2 (hnsPLA) inhibitor with IC50 of 7 nM,. Phase 3.

172732-68-2
DC9874 ML-348(ML348) Featured

ML 348(ML348) is a selective and reversible lysophospholipase 1 (LYPLA1) inhibitor (IC50 = 210 nM).

899713-86-1
DC7574 FIPI Featured

Potent phosholipase D (PLD) inhibitor (IC50 values are 20 and 25 nM for PLD2 and PLD1 respectively).

939055-18-2
DC9590 SPK-601

SPK-601(LMV-601) is a potent phosphatidylcholine-specific phospholipase C (PC-PLC) inhibitor; SPK-601 is useful antimicrobial agent.

1096687-52-3
DC10956 sPLA2-X inhibitor 31

sPLA2-X inhibitor 31 is a potent, selective secreted phospholipase A2 type X (sPLA2-X) with IC50 of 26 nM, displays 12-fold and 80-fold selectivity over sPLA2-Iia and sPLA2-V, respectively.

2241025-50-1
DC7966 U73122

U-73122 is an inhibitor of phospholipase C, phospholipase A2, and 5-LO (5-lipoxygenase).

112648-68-7
DC7591 CAY10650 Featured

CAY10650 is a highly potent (IC50 = 12 nM) cPLA2α inhibitor.

1233706-88-1
DC28393 Halopemide

Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent.

59831-65-1
DC28606 MJ33

MJ33 is an active-site-directed, specific, competitive, and reversible phospholipase A2 (PLA2) inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6. MJ33 has a critical effect on inflammatory brain damage.

199106-13-3
DC28607 MJ33 lithium

MJ33 lithium is an active-site-directed, specific, competitive, and reversible phospholipase A2 (PLA2) inhibitor. MJ33 lithium blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6. MJ33 lithium has a critical effect on inflammatory brain damage.

1135306-36-3
DC28752 Lp-PLA2-IN-2

Lp-PLA2-IN-2 is a potent and selective lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 0f 120 nM for recombinant human Lp-PLA2.

2071636-15-0
DC28753 Lp-PLA2-IN-3

Lp-PLA2-IN-3 is a potent and orally bioavailable lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 of 14 nM for recombinant human Lp-PLA2 (rhLpPLA2).

2196245-16-4
Page 1 / Total 1 FirstPrevNextLastGoto